[3-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL)-2-PHOSPHONO-METHYL-PROPYL]-PHOSPHONIC-ACID-SODIUM-SALT
Compound with spectra: 1 NMR
![[3-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL)-2-PHOSPHONO-METHYL-PROPYL]-PHOSPHONIC-ACID-SODIUM-SALT](/api/compound/31Wv2bDhxqy.png?ph=true&h=300&w=458 "[3-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL)-2-PHOSPHONO-METHYL-PROPYL]-PHOSPHONIC-ACID-SODIUM-SALT")
| SpectraBase Compound ID | 31Wv2bDhxqy |
|---|---|
| InChI | InChI=1S/C10H16ClN5O6P2.4Na/c1-12-8-7-9(15-10(11)14-8)16(5-13-7)2-6(3-23(17,18)19)4-24(20,21)22;;;;/h5-6H,2-4H2,1H3,(H,12,14,15)(H2,17,18,19)(H2,20,21,22);;;;/q;4*+1/p-4 |
| InChIKey | SKBOZULNMREQCT-UHFFFAOYSA-J |
| Mol Weight | 487.59460113 g/mol |
| Molecular Formula | C10H12ClN5Na4O6P2 |
| Exact Mass | 486.954212 g/mol |
| Parent InChIKey | FFBIISIICFTESN-UHFFFAOYSA-J |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | Unknown |
[3-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL)-2-PHOSPHONO-METHYL-PROPYL]-PHOSPHONIC-ACID
[4-(2-CHLORO-6-METHYLAMINO-PURIN-9-YLMETHYL)-7-PHOSPHONO-HEPTYL]-PHOSPHONIC-ACID-SODIUM-SALT
[4-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL-METHYL)-7-(DIETHOXY-PHOSPHORYL)-HEPTYL]-PHOSPHONIC-ACID-DIETHYLESTER
[3-(2,6-DICHLORO-PURIN-9-YL)-2-(DIETHOXY-PHOSPHORYLMETHYL)-PROPYL]-PHOSPHONIC-ACID-DIETHYLESTER
2-Chloro-6-benzylamino-9-(2-propynyl)purine
2-Amino-6-azido-9-(3'-fluoro-2'-hydroxypropyl)purine
URHMIYGQTUFSMG-UHFFFAOYSA-N
Dibenzyl-[2'-chloro-9'-methyl-9H-purin-6'-yl]-amine
9H-Purine-9-propanoic acid, .alpha.-amino-6-[[3-methyl-4-[(trimethylsilyl)oxy]-2-butenyl]amino]-, trimethylsilyl ester, [S-(E)]-
(R)-2-Amino-6-chloro-9-[2'-(diisopropylphosphonyl)methoxy-3'-fluoropropyl]purine
| Title | Journal or Book | Year |
|---|---|---|
| Acyclic Analogues of Adenosine Bisphosphates as P2Y Receptor Antagonists: Phosphate Substitution Leads to Multiple Pathways of Inhibition of Platelet Aggregation | Journal of Medicinal Chemistry | 2002 |